Granted Patent
B2
US 8,461,170 · App. 13/196,189 · Granted Jun 11, 2013
Chemical compounds
Inventors:
Brian Aquila (Waltham, MA); Victor Kamhi (Waltham, MA); Bo Peng (Waltham, MA); Timothy Pontz (Waltham, MA); Jamal Carlos Saeh (Waltham, MA); Kumar Thakur (Waltham, MA); Bin Yang (Waltham, MA)
Assignee:
Astrazeneca AB
View Patent ↗
Loading inventors, assignments & file history…
Abstract
The present invention relates to compounds of Formula (I) and/or Formula (Ia): and to their salts, pharmaceutical compositions, methods of use, and methods for their preparation. These compounds inhibit ALK kinase activity, and thus may be used for the treatment of cancer.
Claims (2)
1. A compound, wherein the compound is N-(4-(4-aminopiperidin-1-yl)-2-methoxyphenyl)-5-chloro-4-(1H-indol-3-yl) pyrimidin-2-amine as the trifluoroacetic acid salt.
2. A pharmaceutical composition comprising a compound of claim 1 , and a pharmaceutically acceptable carrier, diluent, or excipient.
Assignments (3)
CORRECTIVE ASSIGNMENT TO CORRECT THE ASSIGNEE: ASTRAZENECA AB PREVIOUSLY RECORDED ON REEL 027114 FRAME 0173. ASSIGNOR(S) HEREBY CONFIRMS THE ASTRAZENECA PHARMACEUTICALS LP.
Recorded Dec 14, 2011
From: AQUILA, BRIAN; KAMHI, VICTOR; PENG, BO; PONTZ, TIMOTHY; SAEH, JAMAL CARLOS; THAKUR, KUMAR; YANG, BIN
To: ASTRAZENECA PHARMACEUTICALS LP
Reel/Frame 027380/0651 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Oct 25, 2011
From: AQUILA, BRIAN; KAMHI, VICTOR; PENG, BO; PONTZ, TIMOTHY; SAEH, JAMAL CARLOS; THAKUR, KUMAR; YANG, BIN
To: ASTRAZENECA AB
Reel/Frame 027114/0173 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Oct 25, 2011
From: ASTRAZENECA PHARMACEUTICALS LP
To: ASTRAZENECA AB
Reel/Frame 027114/0205 →
Continuity (4)
Provisional Application
61369917
· Aug 2, 2010
Provisional Application
61372055
· Aug 9, 2010
Provisional Application
61390944
· Oct 7, 2010